Axitinib |
Adults and children aged 12–17 |
Bosutinib |
Adults only |
Cetuximab |
Adults and children aged 12–17 |
Crizotinib |
Adults and children aged 16–17 |
Dasatinib |
Adults and children aged 13–17 |
Erlotinib |
Adults and children aged 12–17 |
Nivolumab plus Ipilimumab |
Adults only |
Olaparib |
Adults and children aged 16–17 only |
Palbociclib |
Adults only |
Pembrolizumab |
Adults and children aged 12–17 |
Regorafenib |
Adults and children aged 12–17 |
Sunitinib |
Adults and children aged 12–17 |
Temsirolimus |
Adults and children aged 12–17 |
Trastuzumab plus Pertuzumab |
Adults only |
Vemurafenib plus Cobimetinib |
Adults only |
Vismodegib |
Adults and children aged 12–17 |